Absence of primary integrase resistance mutations in HIV type 1-infected patients in Venezuela

AIDS Research and Human Retroviruses

Volumn 26, Issue 8, 2010, Pages 923-926

  Rangel, Héctor R ^a   Garzaro, Domingo ^a   Fabbro, Rona ^a   Martinez, Nahir ^b   Ossenkop, John ^b   Torres, Jaime R ^b   Gutiérrez, Cristina R ^c   Pujol, Flor H ^a  

^a Instituto Venezolano de Investigaciones Cientificas Centro de Microbiologia y Biologia Celular   (Venezuela)

^b UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

^c Instituto Nacional de Higiene Rafael Rangel   (Venezuela)

Author keywords

[No Author keywords available]

Indexed keywords

INTEGRASE; INTEGRASE INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS DNA;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; FEMALE; GENETIC POLYMORPHISM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PHYLOGENY; PREVALENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VENEZUELA; VIRUS MUTATION; DRUG EFFECTS; GENETICS; HIV INFECTIONS; MOLECULAR GENETICS; MULTIDRUG RESISTANCE; MUTATION; VIROLOGY;

DNA, VIRAL; DRUG RESISTANCE, MULTIPLE, VIRAL; HIV INFECTIONS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; VENEZUELA;

EID: 77955623810     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2010.0039     Document Type: Article

References (12)

1. Rangel HR, Garzaro D, Gutiérrez CR, Vásquez L, Guillen G, Torres JR, and Pujol FH: HIV diversity in Venezuela: Predominance of HIV type 1 subtype B and genomic characterization of non-B variants. AIDS Res Hum Retroviruses 2009;25:347-350.
2. Rangel HR, Garzaro DJ, Torres JR, Castro J, Suarez JA, Naranjo L, Ossenkopp J, and Martinez N: Resistance Committee Group, Gutierrez C, and Pujol FH: Prevalence of antiretroviral drug resistance among treatment-naive and treated HIV-infected patients in Venezuela. Mem Inst Oswaldo Cruz 2009;104:522-525.
3. Cane PA: New developments in HIV drug resistance. J Antimicrob Chemother 2009;64:Si37-Si40.
4. Swanson P, Devare SG, and Hackett J Jr: Molecular characterization of 39 HIV isolates representing group M (subtypes A-G) and group O: Sequence analysis of gag p24, pol integrase, and env gp41. AIDS Res Hum Retroviruses 2003;19:625-629.
5. Rhee SY, Liu TF, Kiuchi M, Zioni R, Gifford RJ, Holmes SP, and Shafer RW: Natural variation of HIV-1 group M integrase: Implications for a new class of antiretroviral inhibitors. Retrovirology 2008;5:74.
6. Passaes CB, Guimarães ML, Fernandez SL, Lorete Rdos S, Teixeira SL, Fernandez JC, and Morgado MG: Lack of primary mutations associated with integrase inhibitors among HIV-1 subtypes B, C, and F circulating in Brazil. J Acquir Immune Defic Syndr 2009;51:7-12.
7. van Hal SJ, Herring B, Deris Z, Wang B, Saksena NK, and DwyerDE:HIV-1 integrase polymorphisms are associated with prior antiretroviral drug exposure. Retrovirology 2009;6:12.
8. Ceccherini-Silberstein F, Malet I, D Arrigo R, Antinori A, Marcelin AG, and Perno CF: Characterization and structural analysis of HIV-1 integrase conservation. AIDS Rev 2009;11: 17-29.
9. Garrido C, Geretti AM, Zahonero N, Booth C, Strang A, Soriano V, and De Mendoza C: Integrase variability and susceptibility to HIV integrase inhibitors: Impact of subtypes, antiretroviral experience and duration of HIV infection. J Antimicrob Chemother 2010;65(2):320-326.
10. Low A, Prada N, Topper M, Vaida F, Castor D, Mohri H, Hazuda D, Muesing M, and Markowitz M: Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors. Antimicrob Agents Chemother 2009;53:4275-4282.
11. Piantadosi A, Humes D, Chohan B, McClelland RS, and Overbaugh J: Analysis of the percentage of human immunodeficiency virus type 1 sequences that are hypermutated and markers of disease progression in a longitudinal cohort, including one individual with a partially defective Vif J Virol 2009;83:7805-7814.
12. Rangel HR, Garzaro D, Fabro R, Fernández D, Gutiérrez CR, Martínez N, and Pujol FH: Comparative analysis of polymorphisms in the HIV type 1 pol gene in the proviral DNA and viral RNA in the peripheral compartment. AIDS Res Hum Retroviruses 2009;25:837-841.